ArticleEuropean heart journal. Digital health2026
Extended and comprehensive e-Health modalities to improve outcome in patients with worsened heart failure: design and rationale of the EXCEED-HF study.
Article in European heart journal. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Remote monitoring (RM) strategies, such as telemonitoring and nurse-guided home care, aim to detect worsening heart failure (WHF) events early on to prevent hospitalization. Previous studies on RM strategies demonstrated benefits, but they were conducted before the widespread adoption of contemporary heart failure (HF) therapies. The EXCEED-HF study, which we present in this manuscript, evaluates whether an extended RM intervention-combining telemonitoring, nurse-guided care, and a digital communication platform-reduces WHF episodes and mortality within 180 days in patients with recent WHF. Methods and results: A single-centre, open-label, randomized controlled trial in patients aged >18 years with chronic or newly diagnosed HF, treated with intravenous diuretics within the past 7 days. A total of 244 patients will be randomized in a 1:1 ratio to receive either the extended RM intervention additional to standard of care (SoC) or SoC alone. The extended RM intervention consists of a combination of telemonitoring, nurse-guided home care, and a multidisciplinary digital communication platform. Primary endpoint is time to all-cause mortality or WHF episode at 180 days. Secondary endpoints include the total number of WHF events, all-cause hospitalizations, quality of life, medication adherence, caregiver satisfaction, and cost-effectiveness at 180 days. Cox proportional hazards and Poisson regression will be used for primary endpoint analyses, following intention-to-treat principles. Sensitivity analyses will include per-protocol assessment. Conclusion: EXCEED-HF evaluates whether a multimodal extended RM intervention additional to SoC reduces mortality and WHF events within the context of contemporary guideline-directed HF therapy. Trial registration number: NL-OMON51343.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.